Click here for the CME evaluation / post-test

Activity Index
Click on the titles below to view the presentations.

The clinical challenges in CLL today

Susan O’Brien, MD

Debate: What should be the standard of care for first line therapy of CLL?

Fludarabine-based combinations
Susan O’Brien, MD

Non-fludarabine based therapies
Martin Dyer, MD

Debate: Should biologic & molecular prognostic markers be used to assign and guide therapy for CLL patients?

Yes – Stephan Stilgenbauer, MD
No – Mark A. Weiss, MD

Debate: Is it necessary to treat to MRD negativity to achieve maximal clinical benefit in CLL?

Yes – Martin Dyer, MD
No – Alessandra Ferrajoli, MD

Emerging novel therapies for CLL

John Byrd, MD

CLL: A vision for the future cases and panel discussion

Susan O’Brien, MD

 

 

Click here for the CME evaluation / post-test